Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
2013 Science
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
2013 Standout
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases
2016 Standout
Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?
2016
Anti-cancer natural products isolated from chinese medicinal herbs
2011 Standout
(−)‐Tarchonanthuslactone: Design of New Analogues, Evaluation of their Antiproliferative Activity on Cancer Cell Lines, and Preliminary Mechanistic Studies
2015
Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820
2019
Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor
2014 StandoutNobel
The inhibitors of apoptosis (IAPs) as cancer targets
2007
RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis
2011
Advances and challenges in targeting FGFR signalling in cancer
2017
Mechanism and medical implications of mammalian autophagy
2018 Standout
PARP inhibitor combination therapy
2016
Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials
2012 Standout
Targeting IAP proteins for therapeutic intervention in cancer
2012
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
2016
ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer
2017
Olaparib: First Global Approval
2015
IAP-targeted therapies for cancer
2008
Marine natural products
1990 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
In silico discovery of acylated flavonol monorhamnosides from Eriobotrya japonica as natural, small-molecular weight inhibitors of XIAP BIR3
2010
Pancreatic cancer
2016 Standout
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
2018
mTOR at the nexus of nutrition, growth, ageing and disease
2020 Standout
EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: A case–control study of overall survival
2013
A Novel Nanoparticle Drug Delivery System: The Anti-inflammatory Activity of Curcumin Is Enhanced When Encapsulated in Exosomes
2010 Standout
Molecular mechanisms of cisplatin resistance
2011 Standout
The complexity of NF-κB signaling in inflammation and cancer
2013 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Antibody therapy of cancer
2012 Standout
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab
2011
mTOR Signaling in Growth, Metabolism, and Disease
2017 Standout
Discovery of curcumin, a component of golden spice, and its miraculous biological activities
2011 Standout
Apoptosis in cancer: from pathogenesis to treatment
2011 Standout
The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells
2013
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
2014
Targeting the apoptosis pathway in hematologic malignancies
2013
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Drug repurposing: progress, challenges and recommendations
2018 Standout
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
2016 Nature
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
2013
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy
2009
Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins
2008
Applications of machine learning in drug discovery and development
2019 Standout
Targeting ferroptosis as a vulnerability in cancer
2022 Standout
Curcumin and Cancer Cells: How Many Ways Can Curry Kill Tumor Cells Selectively?
2009
AKT/PKB Signaling: Navigating the Network
2017 Standout
Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases
2008 Standout
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Multi‐targeted therapy by curcumin: how spicy is it?
2008
Clinical pharmacokinetics of tyrosine kinase inhibitors
2009
Autophagy: controlling cell fate in rheumatic diseases
2016
The PI3K Pathway in Human Disease
2017 Standout
Discovery and resupply of pharmacologically active plant-derived natural products: A review
2015 Standout
Survivin: A new target for anti-cancer therapy
2009
Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery
2020 StandoutNobel
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
2020 Standout
Radiomics: the bridge between medical imaging and personalized medicine
2017 Standout
Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer
2015
A Randomized, Pilot Study to Assess the Efficacy and Safety of Curcumin in Patients with Active Rheumatoid Arthritis
2012 Standout
Quantitative Characterization of Olaparib in Nanodelivery System and Target Cell Compartments by LC-MS/MS
2019
The MAPK pathway across different malignancies: A new perspective
2014 Standout
Apoptosis: A Target for Anticancer Therapy
2018 Standout
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
2014 Standout
Highly Fluorous Porphyrins as Model Compounds for Molecule Interferometry
2011 StandoutNobel
Bright Side of Lignin Depolymerization: Toward New Platform Chemicals
2018 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Communication in the Cancer Microenvironment as a Target for Therapeutic Interventions
2020
Glycol Porphyrin Derivatives as Potent Photodynamic Inducers of Apoptosis in Tumor Cells
2008
In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450
2017
Curcumin, an active component of turmeric (Curcuma longa), and its effects on health
2015 Standout
ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties
2021 Standout
Induction of Apoptosis by Sinulariolide from Soft Coral through Mitochondrial-Related and p38MAPK Pathways on Human Bladder Carcinoma Cells
2012
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
The Inhibitor of Apoptosis Proteins as Therapeutic Targets in Cancer
2007
Chemistry and Biology Of Multicomponent Reactions
2012 Standout
Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature
2008 Standout
Works of Emma Dean being referenced
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
2015
A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC
2009
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
2012
Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic
2007
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of epithelial origin
2009
A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors
2016
IAPs as a Target for Anticancer Therapy
2007
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
2016
Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors
2015
Biomarkers of apoptosis
2008
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study
2010
Biomarkers of cell death applicable to early clinical trials
2012
Phase I study to determine the bioavailability and tolerability of a tablet formulation of the PARP inhibitor olaparib in patients with advanced solid tumors: Dose-escalation phase.
2012
Pharmacokinetic (PK) effects and safety of olaparib in combination with tamoxifen, anastrozole, or letrozole: Phase I study.
2016
Abstract LB-66: Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors .
2013
Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640.
2016
A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers.
2015
A phase I, dose escalation study to determine the maximum tolerated dose of erlotinib when combined with pertuzumab in previously treated non-small-cell lung cancer patients
2008
Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors
2013
A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors
2014
First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors.
2012
Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer
2009
Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors .
2013